Cargando…

The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study

BACKGROUND: Lung fibrosis is a sequela of COVID-19 among patients with severe pneumonia. Idiopathic pulmonary fibrosis and lung fibrosis due to COVID-19 may share many similar features. There are limited data on effects of antifibrotic treatment of infection-related lung fibrosis. This study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saiphoklang, Narongkorn, Patanayindee, Pimchanok, Ruchiwit, Pitchayapa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529527/ https://www.ncbi.nlm.nih.gov/pubmed/36199668 http://dx.doi.org/10.1155/2022/9972846

Ejemplares similares

Patient characteristics and outcomes of a home mechanical ventilation program in a developing country
por: Saiphoklang, Narongkorn, et al.
Publicado: (2019)

Smoking characteristics and lung functions among university athletes
por: Saiphoklang, Narongkorn, et al.
Publicado: (2020)

Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease
por: Saiphoklang, Narongkorn, et al.
Publicado: (2022)

Incidence and outcome of weaning from mechanical ventilation in medical wards at Thammasat University Hospital
por: Saiphoklang, Narongkorn, et al.
Publicado: (2018)

Eosinophilia and parasitic infestations in patients with chronic obstructive pulmonary disease
por: Saiphoklang, Narongkorn, et al.
Publicado: (2020)

Handgrip strength cutoff value predicting successful extubation in mechanically ventilated patients
por: Saiphoklang, Narongkorn, et al.
Publicado: (2021)

Correlation between Handgrip Strength and Rapid Shallow Breathing Index for Assessment of Weaning from Mechanical Ventilation
por: Saiphoklang, Narongkorn, et al.
Publicado: (2021)

Comparison between 20 and 30 meters in walkway length affecting the 6-minute walk test in patients with chronic obstructive pulmonary disease: A randomized crossover study
por: Saiphoklang, Narongkorn, et al.
Publicado: (2022)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Prediction of optimal continuous positive airway pressure in Thai patients with obstructive sleep apnea
por: Saiphoklang, Narongkorn, et al.
Publicado: (2021)

Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib
por: Bourne, Michael H., et al.
Publicado: (2021)

NINTEDANIB AS AN ADJUNCT TREATMENT IN IMPROVING LUNG FUNCTION OF POST-COVID-19 PULMONARY FIBROSIS IN AN ELDERLY PATIENT: A CASE REPORT
por: CYRIL VITUG, LAWRENCE, et al.
Publicado: (2021)

Effects of Nintedanib in an Animal Model of Liver Fibrosis
por: Wollin, Lutz, et al.
Publicado: (2020)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Correlation between Hand Grip Strength and Peak Inspiratory Flow Rate in Patients with Stable Chronic Obstructive Pulmonary Disease
por: Suriyakul, Apisara, et al.
Publicado: (2022)

Effectiveness and Safety of Pirfenidone and Nintedanib for Pulmonary Fibrosis in COVID-19-Induced Severe Pneumonia: An Interventional Study
por: Choudhary, Rajkamal, et al.
Publicado: (2022)

Protective Effects of Nintedanib against Polyhexamethylene Guanidine Phosphate-Induced Lung Fibrosis in Mice
por: Kim, Hyeon-Young, et al.
Publicado: (2018)

Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study
por: Umemura, Yutaka, et al.
Publicado: (2021)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
por: Hostettler, Katrin E, et al.
Publicado: (2014)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
por: Serra López-Matencio, José M., et al.
Publicado: (2021)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
por: Cameli, Paolo, et al.
Publicado: (2022)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
por: Imai, Ryosuke, et al.
Publicado: (2020)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
por: Ogata, Hiroaki, et al.
Publicado: (2021)

Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
por: Kato, Kosuke, et al.
Publicado: (2021)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ltc9dc9d685bdn7gnhbfbhhbf4